FDA hold puts Aardvark Prader-Willi drug in limbo

Aardvark's drug for Prader-Willi syndrome is currently on hold by the FDA due to safety concerns, putting the company's late-stage study in limbo. The unblinding of the study could potentially lead to significant changes in Aardvark's development strategy moving forward.